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 P P+Cis P+Cb
Median age (range) (years) 63.0 (31, 85) 59.5 (26, 77) 61.0 (25, 80)
Male (%) 75.9 75.6 81.3
Karnofsky performance status ≥ 80, 
% of pts* 74.5 81.8 81.7
RR, % of pts (95% CI) 12.1 (9.1,15.7) 23.8 (17.3, 31.4) 16.8 (12.7, 21.7)
Disease control rate (responders 
+SD), % of pts, (95% CI) 58.1 (53.0, 63.0) 67.5 (59.5, 74.9) 66.3 (60.5, 71.8)
One-year survival rate, % (95% CI) 54.7 (42.6, 66.8) 67.9 (48.6, 85.5) 65.5 (54.6, 76.5)
Median TtPD (months) (95% CI) 4.9 (4.2, 5.8) 7.4 (5.6, 10.4) 6.9 (6.2, 7.4)
Leukopenia, Gr 3/4, % of pts 13.9 11.0 18.6
Neutropenia, Gr 3/4, % of pts 15.6 19.9 31.8
Thrombocytopenia, Gr 3/4, % of pts 4.9 12.9 18.6
Anemia, Gr 3/4, % of pts 9.2 10.4 12.4
*Approximately 95% of pts in each treatment arm contributed PS data.
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Background: Tumor growth in MPM presents technical challenges in 
measuring tumor volume or response radiographically even when using 
advanced imaging techniques. Additionally, MPM is highly symptom-
atic with nearly all patients presenting with three or more symptoms. 
Of major symptoms, dyspnea is rated by patients as having the greatest 
severity (Gralla ASCO 2003). Prior analyses indicated that improve-
ment in Forced Vital Capacity (FVC) correlated with improvements in 
patient-reported dyspnea (Gralla WCLC 2005) and that radiological 
response correlated with improvements in FVC (Paoletti ASCO 2003). 
This analysis was undertaken to determine whether dyspnea and other 
PROs of the 8-item LCSS-Meso and PFTs can enhance or replace 
radiological evaluation in monitoring response to therapy.
Methods: We analyzed data from 410 patients from the randomized 
MPM trial of cisplatin ± pemetrexed (Vogelzang JCO 2003). Changes 
from baseline in PROs and FVC were calculated at the time of response 
for patients with an investigator-determined radiological major re-
sponse (PR), at ﬁrst evidence of at least stable disease (SD) for patients 
with best response of SD, or at discontinuation for patients with best 
response of progressive disease (PD). PROs considered are reported in 
the table. Changes in PROs were summarized by radiological sub-
group which were further restricted to patients with or without an FVC 
improvement of at least 5%. Discriminant analyses were conducted to 
classify patients into two groups: PR+SD vs PD using changes in PROs 
and FVC as predictors. Prediction rates from the discriminant analyses 
were calculated as the number of correctly classiﬁed patients divided 
by total sample size. 
Results: PRs alone reported smaller PRO changes than those PRs 
with 5% improvement in FVC for dyspnea, pain, and symptom 
distress. Those with PD alone reported similar change to those with 
PD and&nbsp; < 5% improvement in FVC. The highest prediction 
rate (78.4%) was achieved by a combination discriminant of patient-
reported dyspnea and FVC; however, combining either two PROs 
(ie, dyspnea and activity level) or all PROs achieved nearly the same 
prediction rate (77% and 78%, respectively).
Mean Changes from Baseline and Prediction Rates
Item
PR (n=125) 
(A)
PR and >5% 
FVC (n=49) 
(A)
PD (n=120) 
(A)
PD and <5% 
FVC (n=50) 
(A)
Prediction 
Rate (%) (B)
Dyspnea 6.4 11.6 -18.8 -21.8 73.1
Fatigue 1.5 1.9 -22.0 -22.7 71.3
Pain 11.1 16.9 -12.3 -15.1 71.0
Symptom 
distress 5.8 9.2 -16.5 -16.2 67.3
Activity level 3.7 1.8 -22.6 -22.5 71.9
Global quality 
of life 4.6 1.9 -21.6 -20.4 72.5
All PROs - - - - 78.0
FVC - - - - 67.2
Dyspnea/FVC - - - - 78.4
Dyspnea/ 
Activity level - - - - 77.0
A. Visual Analogue Scale (0-100 mm) for each PRO item. Positive value indicates improvement.
B. Number of radiological PR+SD correctly classiﬁed by discriminant plus number of radiological PD 
correctly classiﬁed by discriminant divided by total sample size; sample sizes are approximately 410 for 
PROs and 296 for FVC.
Conclusions: Changes in patient-reported LCSS-Meso items correlate 
with radiological response to therapy. PROs appear to be at least as 
sensitive in predicting response to therapy as objective measures such 
as FVC. The LCSS-Meso may serve as an effective, inexpensive, and 
easy-to-administer alternative to radiological assessment for monitor-
ing response to therapy for MPM. Prospective studies are needed to 
conﬁrm these ﬁndings.
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Background: Selected patients with limited (cT1-3N0) malignant 
pleural mesothelioma are being considered for a multimodality therapy 
with induction chemotherapy followed by extrapleural resection and 
radiotherapy. Since invasion of the mediastinal lymph nodes is a nega-
tive prognostic factor, cervical mediastinoscopy is recommended for 
staging in these patients. Transoesophageal Endoscopic Ultrasound 
with a linear scanning ultrasound endoscope and real time guided ﬁne 
needle aspiration (EUS-FNA) enables mediastinal lymph node staging 
with high accuracy in lung cancer patients. 
